Published in final edited form as:

Semin Nephrol. 2008 March ; 28(2): 133–142.

Bone Disease and Idiopathic Hypercalciuria

Joseph E. Zerwekh, Ph.D.

Professor of Internal Medicine, From the Charles and Jane Pak Center for Mineral Metabolism and Clinical Research University of Texas Southwestern Medical Center 5323 Harry Hines Blvd Dallas, TX 75390-8885

Abstract

Observational and epidemiological studies alike have demonstrated that idiopathic hypercalciuric (IH) stone-forming patients typically demonstrate bone mineral density scores significantly less than those observed for age- and gender-matched normal subjects or those for non-hypercalciuric stone-forming patients. Most of these studies have relied on changes in bone mineral density (BMD) and have not explored the mechanism(s) involved. There have been a small number of studies that have relied on dynamic bone histomorphometry to ascertain the nature of the bone defect in IH patients. When performed, these studies have clearly demonstrated increased bone resorption and high bone turnover in patients with fasting hypercalciuria while suppressed bone formation indices are the most consistent finding in patients with the absorptive variant of IH. The causes of this apparent difference in bone remodeling between the two variants of IH is still uncertain. Available evidence suggests that potential mechanisms may be dependent in large part to genetic, metabolic, and nutritional causes of hypercalciuria and bone loss in patients with IH.

Keywords

osteopenia; hypercalciuric stone-formers; bone histomorphometry; nutrition; genetics

It has been 30 years since the first report of reduced bone mineral content in patients with urolithiasis. This was soon followed by a series of studies from several laboratories that were consistent with the notion that patients with calcium urolithiasis typically have lower bone mineral density (BMD) than normocalciuric stone-formers and their non-stone-forming counterparts. Despite the consistency of these early reports in documenting low BMD among stone-formers, these studies suffered from several limitations including various etiologies for urolithiasis, small patient numbers, differences between instruments used to measure BMD, and other confounders such as body mass and gender. This article will review the evidence supporting the existence of bone loss in patients with urolithiasis, the nature of the defect in bone remodeling contributing to bone loss, and possible mechanisms for such a loss.

Do patients with urolithiasis have reduced BMD?

Several of the earliest studies that assessed BMD in patients with idiopathic hypercalciuria (IH) suggested that bone mass or bone mineral content (BMC) is lower than that observed for age- and gender-matched normal subjects. However, most of these studies did not clearly define

Correspondence should be addressed to: Joseph E. Zerwekh, Ph.D. Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8885, 214-648-3872 214-648-2526 (FAX), joseph.zerwekh@utsouthwestern.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

the underlying mechanism for the hypercalciuria or consistently present urinary calcium data. For example, Alhava et al. (1) used single photon absorptiometry (SPA) to quantitate BMC of the radius in an unselected population of stone-formers. Compared to normals, the stone-formers' BMD at the distal radius was reduced by 5%. Only 5 patients were hypercalciuric at the time of evaluation and some patients had evidence of subtle hyperparathyroidism, a condition that clearly could drive increased bone resorption and decreased BMD, particularly of cortical bone as found in the distal radius. In a study by Fuss et al. (2), SPA of the distal radius in 94 patients with IH demonstrated reduced BMC, especially in patients who had been adhering to a low-calcium diet. Again, this study was somewhat clouded by the inclusion of subjects with fasting hypercalciuria and in whom parathyroid hormone (PTH) concentrations may have been elevated. Another set of studies by Casez et al (3) initially reported a mean z-score reduction of -0.55 at the spine by dual energy x-ray absorptiometry (DEXA) in 94 young calcium stone-formers but in a subsequent study found normal lumbar vertebral BMD in a second group of 99 patients (4). Barkin et al. (5) using neutron activation analysis, reported that BMD was reduced by 5% in 109 patients with recurrent urolithiasis. This report is significant in that neutron activation analysis is considered to be one of the most sensitive methods for assessing bone mineral content. Thus, these studies have shown that a bone mass deficit does exist among hypercalciuric stone-formers although the results probably include patients with mild-moderate hyperparathyroidism.

Several studies have also examined BMD in normocalciuric stone-formers. Again, the findings were mixed with about half of the studies reporting no significant differences in BMD or BMC as compared to age- and gender-matched normal subjects (4,6–9). On the other hand, studies that utilized methods for measuring BMD considered to be more sensitive, found significant reductions of BMD in normocalciuric calcium stone-formers (5,10–13). These studies employed methods such as neutron activation (5), DEXA (13) and single energy quantitative computed tomography (SEQCT). Taken together, these studies suggest that bone loss is present in some normocalciuric stone-forming patients but not of the magnitude observed for patients with IH.

Despite these inconsistent findings in some studies, there appears to be a general consensus of reduced BMD in patients with IH comprised by both fasting and absorptive hypercalciuria variants. Except for two studies that utilized the less sensitive SPA technique (14,15), all other studies have demonstrated that BMD is decreased significantly at the spine and moderately at cortical rich sites (7,10–12,16–20) for stone-forming patients with IH. This observation was found to be true whether patients were considered as a whole or subdivided into those with absorptive hypercalciuria type I (AHI) or fasting hypercalciuria. It should be noted that when this sub classification is made, patients with renal leak or fasting hypercalciuria appear to have a much greater deficit in their BMD as compared to patients with AHI, implicating a role for secondary hyperparathyroidism in contributing to the bone loss. On the other hand, the bone loss in patients with AHI appears to occur despite enhanced intestinal calcium absorption, a fact that underscores a primary defect at the level of the skeleton. In addition, many IH patients are instructed to reduce dietary calcium intake to attenuate their hypercalciuria but in so doing may contribute to enhanced bone loss. This point has been supported by a recent report from Asplin et al. (21). Their study assessed vertebral and femoral neck BMD among relatives and probands in 22 stone-formers (14 of whom were hypercalciuric) and contrasted the results to 37 patients without stones (10 of whom were hypercalciuric). Several interesting findings emerged from this study. There was no difference in mean BMD z-scores at the spine or at the hip between stone-formers and non-stone-formers. Secondly, stone-formers reported reduced dietary calcium intakes when factored for body weight but urinary calcium excretion was comparable among the two groups suggesting that stone-formers were in more negative calcium balance as compared to non-stone-formers. This is consistent with balance studies that have demonstrated that bone of IH patients with stones loses more mineral than normal when

dietary calcium becomes limiting (22). BMD z-scores at the hip and spine were inversely correlated with urinary calcium for stone-formers but not non-stone-formers. Additionally, the BMD z-scores of the femoral neck and spine varied significantly with ammonium excretion for stone-formers but not for non-stone-formers. These findings suggest that a low calcium intake may exaggerate bone loss in hypercalciuric patients and render the skeleton more susceptible to bone loss by other mechanisms such as increased dietary acid intake (23,24).

Based on the foregoing discussion, it is clear that in a majority of these earlier studies patients with IH are at greater risk of sustaining bone loss than compared to non-hypercalciuric subjects. Although many of these studies were performed in few patients with little attempt to characterize the nature of their hypercalciuria, the consistency of findings of reduced BMD in patients with IH strongly supports an association. The significance of this observation lies in the fact that low BMD is a strong risk factor for osteoporotic fracture (25,26). However, both fractures and kidney stones are relatively rare events in the general population and demonstration of an association would require large study populations, best obtained by epidemiological data. Melton et al. (27) used a population-based retrospective cohort study design with data from the Rochester Epidemiology Project to determine rates of fracture among 624 persons diagnosed with kidney stones from 1950 to 1974 in Olmstead County, MN. The risk of vertebral fracture was greatly increased among men who formed kidney stones, standardized mortality ratio (SMR) 7.0 and mildly elevated among women (SMR 2.4). This increased risk for fractures was only observed for the spine and not at non-vertebral sites. A second population-based study in 1309 women failed to disclose any association between BMD and fracture and history of kidney stones (28). Only 44 women were found to have had a history of kidney stones suggesting that the study may have had insufficient power to observe an association with BMD or fractures. A cross-sectional study by Lauderdale et al (29) utilized the NHANES III data to determine whether a history of kidney stones is associated with lower femoral neck BMD or prevalent spine or wrist fracture. There were 793 respondents out of approximately 31,000 that reported a history of kidney stones (477 men, 316 women). They found that men with kidney stone history had lower femoral neck BMD than men without kidney stone history after adjusting for age, body mass index, race/ethnicity and other potential confounders. This was not true for women who formed kidney stones. Men with kidney stone history were also more likely to report prevalent wrist and spine fractures (prevalence odds ratio for spine fracture, 2.32 for men (CI 1.04–5.18) but not for women, 1.75 (CI 0.58–5.29)). The study also asked whether dietary calcium modifies the association between kidney stone history and BMD. There was a positive interaction term for kidney stone history and milk consumption for both men and women but was only significant for men ($p=0.05$). Figure 1 depicts how the interaction term affects the association between level of milk consumption and age-adjusted BMD for men for each level of milk consumption. Thus, men with a history of kidney stones who reported low milk (calcium) intakes had a much lower age-adjusted BMD than men with no kidney stone history underscoring an important nutritional consideration in preventing bone loss and increased fracture risk among male kidney stone patients. This observation is also consistent with the results from two smaller studies discussed above (2, 21).

We can therefore say that there is strong clinical and epidemiological evidence supporting an association of bone loss in idiopathic hypercalciuric stone-forming patients. While these studies have used BMD as the marker of bone loss, these studies cannot shed light on the presumed mechanism for the bone loss at the tissue level.

What is the nature of the defect in bone remodeling in idiopathic hypercalciuric patients?

There have been relatively few studies directed at examining bone remodeling dynamics in IH patients. This is probably the result of the need for controlled diets prior to evaluation, invasive nature of some procedures such as bone biopsy, and lack of willing patients because of relatively mild, asymptomatic bone disease. Two studies have only used biochemical markers of bone turnover. In the study by Jaeger et al. (9) urinary hydroxyproline as well as the collagen crosslinks, pyridinoline and deoxypyridinoline, were measured in both fasting and 24 hour urines from 29 hypercalciuric and 30 non-hypercalciuric stone-formers. There were no significant differences in mean values of these markers between hypercalciuric and non-hypercalciuric stone-formers. However, BMD at the tibial diaphysis was negatively correlated with pyridinoline/creatinine concentration ratio in 24 hour urines and skeletal scores were negatively correlated with fasting hydroxyprolinuria. Although this finding points to increased bone resorption as a cause of the reduced bone mass, subjects were on a free-choice diet during their urine collections, a fact that may have influenced diet sensitive urinary hydroxyproline excretion. Twenty-four hour urinary pyridinoline excretion was also inversely correlated with the skeletal score while the more skeleton specific deoxypyridinoline (30) demonstrated no significant association. More recently, Asplin et al. (21) examined five bone turnover markers in their study including bone specific alkaline phosphatase, c-terminal and n-terminal telopeptides of type I collagen in serum, and total pyridinoline and deoxypyridinoline in urine. They found no differences between any of these markers in stone-formers and non-stone-formers. In addition, none were correlated with BMD z-score of the femoral neck or spine to a significant degree. No assessment was made for hypercalciuric versus nonhypercalciuric subjects. Thus, no clear indication of the nature of the bone defect in IH patients has emerged with the use of these biochemical markers.

Studies that have utilized both static and dynamic bone histomorphometry have also shown mixed results although one aspect of bone turnover has been observed to be a rather consistent finding, namely decreased bone formation in subjects with IH. Bordier et al. (31) performed bone biopsy on 47 calcium stone-formers with IH. For the whole group, biopsy findings were within normal limits. However, when patients were divided into those with renal leak hypercalciuria and absorptive hypercalciuria secondary to renal phosphate leak, two distinctive patterns of bone turnover emerged. Patients with elevations in PTH disclosed increased osteoclastic and osteoblastic surfaces consistent with high bone turnover. On the other hand, there appeared to be a defect in bone formation for the patients with renal phosphate leak and intestinal hyperabsorption of calcium. Osteoblastic surfaces were decreased as were osteoid parameters. Although osteoclastic and eroded surfaces were reported as increased, values were within normal age-adjusted limits and may have simply been due to a failure of the resorbed lacunae to fill in the face of low bone formation. De Vernejoul et al. (32) reported static and dynamic parameters for 30 patients with IH. Although immunoreactive PTH was increased in three patients, no sub-classification of these patients was performed.

Trabecular bone volume was mildly decreased whereas osteoid parameters were normal. Despite normal osteoid parameters, osteoblastic surface was significantly decreased in the face of normal mineralization. Resorption parameters were decreased for osteoclastic surface but normal for eroded surfaces. The authors suggested that cancellous bone volume was decreased due to decreased bone formation in the face of normal bone resorption. Malluche and colleagues (33) studied 15 patients with IH. These patients were shown to be of the absorptive type by a fall in the calcium to creatinine ratio following cellulose phosphate administration, a non-absorbable calcium binder. Bone biopsy analysis disclosed a defective bone formation as shown by increased osteoid volume and surface and reduced osteoblast numbers. The increased osteoid surface was considered to be inactive since active double labeled tetracycline surfaces

were reduced by nearly one-half. Bone resorption did not appear to be increased. The authors concluded that defective bone formation is present in IH patients with AHI. Perhaps the largest series to date is that of Steiniche et al. (34). They performed bone biopsy in 33 calcium stone-formers while on a random diet and compared the values to those obtained in 30 age- and sex-match control subjects. These patients displayed normal PTH and serum phosphate but increased phosphaturia as well as hypercalciuria. Therefore their hypercalciuria was probably either dietary or idiopathic in origin, but probably not of the renal leak type. Their histomorphometric data showed decreased bone formation rates and increased mineralization lag times. Total resorption surfaces were also increased but again probably the result of defective refilling of the lacunae in the face of low bone formation.

Two additional studies composed of small numbers of patients used bone density measurements in addition to bone histomorphometry. As expected, BMD was low for the IH patients in both series (20,35). Although bone formation was low in both series, the six men in the Heilberg study (20) had fasting hypercalciuria and increased osteoclastic bone resorption suggesting dissociation between bone resorption and formation. The five calcium stone-formers in the Da Silva study (35) demonstrated defective mineralization and increased osteoid and resorption surfaces. Another study by Bataille et al. (36) studied 24 hypercalciuric calcium stone-formers because BMD of their vertebrae disclosed a mean z-score of -0.5 by single energy QCT. Twenty-three of the subjects had fasting hypercalciuria and 1 patient had AHI. As a group, trabecular bone volume was decreased on biopsy as well as the osteoid parameters and bone resorption surfaces. Dynamic parameters were consistent with decreased bone formation and mineral apposition rate without a significant increase of mineralization lag time. These findings are somewhat surprising in light of the fasting hypercalciuria present in most of the patients in the Bataille study since increased bone resorption would be expected to be found. However, hydroxyprolinuria was shown to be increased in these patients despite relatively normal bone resorption surfaces on bone biopsy. This latter finding serves well to emphasize the discordance that is often seen between histomorphometric indices of bone resorption and that obtained from biochemical markers of bone turnover.

In order to help resolve the contribution of bone to fasting hypercalciuria in patients with AHI, Heller and colleagues (37) obtained bone biopsies on nine stone-formers with AHI and on nine matched control subjects. Patients were then studied after stabilization on a low-calcium (400 mg/d) diet in an inpatient setting at the General Clinical Research Center for evaluation of calcium homeostasis before and following blockade of bone resorption with alendronate (10 mg daily for 17 days). Bone biopsy analysis disclosed that compared with controls, stone-formers had decreased indices of bone formation (osteoblast surface/bone surface 1.8 ± 2.1 vs $3.0 \pm 1.5\%$, $p=0.04$, mean wall thickness 36 ± 7 vs 47 ± 8 μm , $p=0.001$) and relatively higher bone resorption although the mean value was well within normal limits (osteoclastic surface 0.4 ± 0.2 vs $0.2 \pm 0.2\%$, $p=0.05$). A short-term course of alendronate treatment corrected fasting hypercalciuria and reduced 24 hour urinary calcium by 48 mg/d. However, increased intestinal calcium absorption persisted and calcium balance improved significantly. These studies not only support the persistent finding of reduced bone formation observed in other studies, but also suggest that the hypercalciuria of AHI originates primarily from intestinal hyperabsorption of calcium, but bone resorption in excess of bone formation may contribute. Indeed Weisinger et al. (38) reported a mean decrease in urinary calcium of 75 to 202 mg/d with an identical dose of alendronate to IH patients. Bushinsky (39) also found that the urinary calcium of hypercalciuric rats fell toward the range of wild-type rats after treatment with subcutaneous alendronate, correcting the estimated negative calcium balance. Urinary calcium did not change in normal subjects or normal rats following alendronate in either of these studies.

Thus a majority of the studies that have used bone histomorphometry in IH patients support the notion that the low BMD is due principally to a suppression of bone formation in the face

of relatively normal bone resorption. There are exceptions to this, particularly in the face of fasting hypercalciuria and secondary hyperparathyroidism where bone resorption and formation may be increased.

What mechanisms are responsible for bone loss in IH?

From the foregoing discussion, it is apparent that two general types of bone remodeling defects are present in patients with IH and are dependent on the nature of the hypercalciuria. For those with a clear picture of renal hypercalciuria resulting from either renal calcium leak or from increased filter load of calcium, the remodeling defect is consistent with one of increased bone turnover while in those with the absorptive form of hypercalciuria, the defect appears to be more consistent with defective bone formation in the presence of normal or inappropriately elevated bone resorption. Several possible mechanisms have been proposed to explain these differing responses in bone turnover. In renal hypercalciuria, there is an increase in bone turnover believed to be secondary to an increase in PTH secretion to maintain serum ionized calcium concentration. Bone biopsy analysis in osteoporotic patients with renal calcium leak and secondary hyperparathyroidism has disclosed increased bone turnover that resolves with hydrochlorothiazide treatment (40). However, there are additional circumstances under which a renal hypercalciuric picture might emerge associated with increased skeletal turnover.

High animal protein intake

A high animal protein diet is known to cause hypercalciuria. Several mechanisms have been invoked to explain the hypercalciuria but it appears to be mainly derived from both bone and renal loss mechanisms resulting from a systemic acid load (41). High dietary protein intake causes glomerular hyperfiltration, which results in increased filtered load of calcium and hypercalciuria. However, the hypercalciuria seen under high dietary protein intake is much greater than that predicted to occur only from increased filter load to the kidney (42). This suggests that there may be a direct acid-mediated inhibition of renal tubule calcium reabsorption. Recent studies have confirmed that an acid load inhibit the renal reabsorption of calcium (43) and promotes a sharp increase in bone turnover in an animal model (42). Furthermore, in a recent clinical study (44), a high protein-low carbohydrate weight reducing diet increased net acid excretion by 54 mEq/d and reduced urinary pH by 0.5 units. While urinary calcium increased by 90 mg/d, intestinal calcium absorption was not altered, suggesting that the hypercalciuria was of skeletal origin. We have recently reported on the deleterious effects of high protein intake on the skeleton using static and dynamic based bone histomorphometry (42). Protein excess was produced in rats by feeding a high casein diet. Compared with a low casein diet, urinary calcium was 3 to 4-fold greater on a high casein diet that was high in acid ash content. The increase in bone resorption as assessed by eroded surfaces and active osteoclastic surfaces was quite dramatic, with each of these parameters being increased 3-fold or better (Figure 2). In a preliminary study, Zerwekh et al. (45) have demonstrated that neutralization of the acid load by co-administration of potassium citrate, completely prevented hypercalciuria, cancellous bone loss and the rise in bone resorption parameters. It is interesting to also note that in three previous studies mentioned above, where it was asked whether an association between acid intake and BMD existed, that those results are consistent with such an association. Pietschmann et al. (7) found an inverse association between vertebral BMD and 24 hour urinary sulfate and pH. Jaeger et al. (9) also demonstrated an inverse association between these biochemical markers of increased acid load and corrected BMD at the tibia and femur. In Asplin's study, no significant relation was seen between BMD z-scores of the femoral neck or spine with urinary sulfate or titratable acid, but an inverse significant correlation was found for total ammonium versus femoral neck and vertebral BMD z-score in stone-formers (21). Non-stone-formers did not demonstrate such an association. Finally, Sakhae et al. (46) have reported that potassium alkali administration (40 mmol/d) to

postmenopausal women significantly decreased urinary calcium without changing serum PTH. In this study potassium alkali alone had little effect on bone turnover markers although it did reduce serum carboxyterminal extension peptide of type I collagen (a marker of bone resorption) by about 10%.

PGE₂ excess

Another potential sequela of high protein intake is increased renal production of PGE₂. Intra-arterial administration of PGE₂ in experimental animals has been shown to increase urinary calcium excretion without changes in glomerular filtration rate (47). Under conditions of high animal protein intake (increased acid load), PGE₂ may serve to exacerbate the acid-load induced hypercalciuria by increasing the sensitivity of the epithelial calcium channel to inhibition by acid. Prostaglandins also have potent skeletal effects. Their actions on osteoclasts and osteoblasts have been shown to be mixed, depending on the model used (cell culture, organ culture, whole animal). Most studies have suggested that PGE₂ is a potent stimulator of bone resorption (48) while inhibiting osteoblastic collagen synthesis (49). Whether a high animal protein diet can raise systemic PGE₂ concentrations sufficiently to affect the bone remodeling process is currently unknown.

Other potential causes

Other reports have suggested that the bone loss seen in IH patients with stones may be intrinsic to the underlying cause of the hypercalciuria. Several factors, including IL-1, IL-6, tumor necrosis factor- α , granulocyte macrophage colony stimulation factor, and fatty acids have been intimated to promote hypercalciuria and bone loss, the latter through increased bone resorption and turnover (12,47,50–52). While these potential mechanisms are consistent with increased bone turnover, they may not explain the low bone formation that has been reported for a majority of patients with AHI.

Potential causes of low bone formation in AHI

As discussed above bone biopsies from patients with AHI have shown a picture compatible with low bone formation and turnover while features suggestive of increased bone resorption are less common. At the cellular level, decreased bone formation may result from reduced osteoblast numbers, decreased work function per osteoblast, and/or increased osteoblast apoptosis. To date, there has not been an assessment of osteoblast apoptosis in bone biopsies from patients with AHI. Malluche (33) suggested that in patients with nephrolithiasis and stones, the bone biopsy was consistent with decreased work function per osteoblast while in Heller's study (37) it was more consistent with decreased osteoblast numbers. At the molecular level, the number of base changes in the AH related adenylyl cyclase (AHRAC) has been shown to be well correlated with reduced spinal bone density (53). Among AH patients with intestinal hyperabsorption of calcium, patients harboring AHRAC base substitutions had much lower bone density than those with wild type AHRAC genotypes. AHRAC is expressed in bone but its current function in bone cells is currently not known. It is conceivable that dysfunction of AHRAC can alter the rate of bone formation that produces an inappropriately high bone resorption in AHI (37).

Another potential cause is elevated serum 1,25-dihydroxyvitamin D [1,25(OH)₂D] or increased sensitivity to its actions. At high doses, this hormonal regulator of intestinal calcium absorption may increase bone resorption and decrease collagen synthesis (54). Administration of 1,25 (OH)₂D to normal volunteers mimics the AHI phenotype (55). Some 30–80% of patients with AHI have elevations in this vitamin D metabolite due to disordered regulation (56,57). Vitamin D receptor concentrations have been reported to be increased in IH patients in some studies (58) but not in another study (59). Increased vitamin D receptor concentration and increased sensitivity of bone (60,61) have also been shown in an animal model of hypercalciuric

nephrolithiasis, namely the genetic hypercalciuric stone-forming rat. Thus, in patients with high 1,25(OH)₂D or increased receptor number, there may be increased bone resorption compared to normal subjects and possibly reduced collagen synthesis similar to the reduced bone formation observed in AHI stone-forming patients. Additional studies with both human and animal models of AHI will be needed to further explore what mechanisms may be contributing to the bone loss observed for this group of stone-forming patients.

Acknowledgements

Supported in part by National Institute of Health grant P01-DK20543

References

1. Alhava EM, Juuti M, Karjalainen P. Bone mineral density in patients with urolithiasis. *Scand J Urol Nephrol* 1976;10:154–156. [PubMed: 948725]
2. Fuss M, Peppersack T, Van Geel J, et al. Involvement of low calcium diet in the reduced mineral content in idiopathic renal stone formers. *Calcif Tissue Int* 1990;46:9–13. [PubMed: 2104775]
3. Casez JP, Hug C, Ackermann D, et al. Bone mineral density of lumbar spine, femoral neck and distal tibia in patients with calcium nephrolithiasis. *Urol Res* 1990;18:66.(abstr)
4. Casez JP, Hug C, Hess B, et al. The myth of low bone mass in idiopathic calcium renal stone formers. *Kidney Int* 1993;44:264.(abstr)
5. Barkin J, Wilson DR, Manuel MA, et al. Bone mineral content in idiopathic calcium nephrolithiasis. *Miner Electrolyte Metab* 1985;11:19–24. [PubMed: 3974535]
6. Velentzas, C.; Oreopoulos, DG.; Meema, S., et al. Dietary calcium restriction may be good for patient's stone but not for their bones. In: Smith, L.; Robertson, WG.; Finlayson, B., editors. *Urolithiasis; Clinical and Basic Research*. New York, NY: Plenum; 1981. p. 847-854.
7. Pietschmann F, Breslau NA, Pak CYC. Reduced vertebral bone density in hypercalciuric Nephrolithiasis. *J Bone Min Res* 1992;7:1383–1388.
8. Alonso, E.; Durrego, P.; Blassini, A., et al. Role of cytokines and type of hypercalciuria in the bone mineral loss of idiopathic hypercalciuria. XIIth International Congress of Nephrology; Jerusalem, Israel. 1993. p. 620(abstr)
9. Jaeger P, Lippuner K, Casez JP, et al. Low bone mass in idiopathic renal stone formers: magnitude and significance. *J Bone Min Res* 1994;9:1525–1532.
10. Fuss M, Gillet C, Simon J, et al. Bone mineral content in idiopathic renal stone disease and in primary hyperparathyroidism. *Eur Urol* 1983;9:32–34. [PubMed: 6822240]
11. Bataille, P.; Bergot, C.; Fournier, A., et al. Lower vertebral density in calcium stone formers with normocalciuria and idiopathic hypercalciuria. In: Dirk, SJM.; Sutham, RH., editors. *Evidence for primary bone resorption in idiopathic hypercalciuria; Proceedings of VIth International Symposium on Urolithiasis*; New York, NY: Plenum; 1988. p. 391-397.
12. Pacific R, Rothstein M, Pifas L, et al. Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. *J Clin Endocrinol Metab* 1990;71:138–145. [PubMed: 2370292]
13. Hess B, Casez JP, Takkinen D, et al. Relative hypoparathyroidism and calcitriol upregulation in hypercalciuric calcium renal stone formers; impact of nutrition. *Am J Nephrol* 1993;13:18–26. [PubMed: 8322837]
14. Lawoyin S, Sismilich S, Browne R, et al. Bone mineral content in patients with calcium urolithiasis. *Metabolism* 1979;28:1250–1254. [PubMed: 514087]
15. Lindergard B, Colleen S, Mansson W, et al. Calcium loading test and bone disease in patients with urolithiasis. *Proc EDTA* 1983;20:460–465.
16. Malvasi L, sartori L, Giannimi S, et al. Mineral metabolism and bone mineral content in calcium nephrolithiasis with or without hyperparathyroidism. *Urol Res* 1988;16:190.(abstr)
17. Bataille D, Achard JM, Fournier A, et al. Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. *Kidney Int* 1991;39:1193–1205. [PubMed: 1895673]

18. Borghi L, Meschi T, Guerra A, et al. Vertebral mineral content in diet-dependent and diet-independent hypercalciuria. *J Urol* 1991;46:1334–1338. [PubMed: 1942285]
19. Audran M, Bataille P, Sebert JL, et al. La densité osseuse dans l'hypercalciurie idiopathique chez l'homme. *Rev Rhum* 1991;58:747–750. [PubMed: 1780648]
20. Heilberg IP, Martini LA, Szejnfeld VL, et al. Bone disease in calcium stone forming patients. *Clin Nephrol* 1994;42:175–182. [PubMed: 7994936]
21. Asplin JR, Bauer KA, Kinder J, et al. Bone mineral density and urine calcium concentration among subjects with and without hypercalciuria. *Kidney Int* 2003;63:662–669. [PubMed: 12631132]
22. Asplin, JR.; Coe, FL.; Favus, M. Nephrolithiasis. In: Brenner, BM., editor. *The Kidney*. 6. Philadelphia, Pennsylvania: W.B. Saunders; 2000. p. 1774-1819.
23. Bushinsky DA, Lechleider RJ. Mechanism of proton-induced bone calcium release: calcium carbonate dissolution. *Am J Physiol* 1987;253:F998–F1005. [PubMed: 2825542]
24. Goldhaber P, Rabadjija L. H^+ stimulation of cell-mediated bone resorption in tissue culture. *Am J Physiol* 1987;253:E90–E98. [PubMed: 3605336]
25. Melton LJ III, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral density assessed at different skeletal sites. *J Bone Min Res* 1993;8:1227–1233.
26. Cummings SR, Black DM, Nevitt L, et al. Bone density at various sites for prediction of hip fractures. *Lancet* 1993;341:72–75. [PubMed: 8093403]
27. Melton LJ III, Crowson CS, Khosla S, et al. Fracture risk among patients with urolithiasis: a population-based cohort study. *Kidney Int* 1998;53:459–464. [PubMed: 9461107]
28. Sowers MR, Jannausch M, Wood C, et al. Prevalence of renal stones in a population-based study of dietary calcium, oxalate, and medication exposures. *Am J Epidemiol* 1998;147:914–920. [PubMed: 9596469]
29. Lauderdale DS, Thisted RA, Wen M, et al. Bone mineral density and fracture among prevalent kidney stone cases in the third national health and nutrition examination survey. *J Bone Min Res* 2001;16:1893–1898.
30. Garnero P, Delmas PD. Biochemical markers of bone turnover applications for osteoporosis. *Endocrinol Metab Clin North Am* 1998;27:303–323. [PubMed: 9669140]
31. Bordier P, Ryckewart A, Gueris J, et al. On the pathogenesis of so-called idiopathic hypercalciuria. *Am J Med* 1977;63:398–409. [PubMed: 900144]
32. De Vernejoul MC, Hioco D, Villaumey J, et al. Etude histomorpométrique osseuse au cours de l'hypercalciurie idiopathique. *Rev Rhum* 1981;48:389–395. [PubMed: 7256148]
33. Malluche HH, Tschoepe W, Ritz E, et al. Abnormal bone histology in idiopathic hypercalciuria. *J Clin Endocrinol Metab* 1980;50:654–658. [PubMed: 6245099]
34. Steiniche T, Mosekilde L, Christensen MS, et al. A histomorphometric determination of iliac bone remodeling in patients with recurrent renal stone formation and idiopathic hypercalciuria. *Acta Pathol Microbiol Immunol Scand* 1989;97:309–316.
35. Da Silva, AMM.; Dos Reis, LM.; Pereira, RC., et al. Bone histomorphometric and bone mineral content in idiopathic hypercalciuria patients. XIIth International Congress of Nephrology; Jerusalem, Israel. 1993. p. 620(abstr)
36. Bataille P, Hardy P, Marie A, et al. Decreased bone formation in idiopathic hypercalciuric calcium stone formers explains reduced bone density. *J Bone Min Res* 10(suppl1):401.(abstr)
37. Heller HJ, Zerwekh JE, Gottschalk FA, et al. reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. *Kidney Int* 2007;71:808–815. [PubMed: 17311067]
38. Weisinger JR, Alonzo E, Machado C, et al. Papel de hueso en la fisiopatología de la hipercalciuria idiopática: efecto del aminobisfosfonato alendronato. *Medicina* 1997;57(Suppl 1):45–48. [PubMed: 9567354]
39. Bushinsky DA, Neumann KJ, Asplin J, et al. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. *Kidney Int* 1999;55:234–243. [PubMed: 9893132]
40. Sakhaee K, Nicar MJ, Glass K, et al. Postmenopausal osteoporosis as a manifestation of renal hypercalciuria with secondary hyperparathyroidism. *J Clin Endocrinol Metab* 1985;61:368–373. [PubMed: 4008611]

41. Lemann J Jr, Litzow JR, Lennon EJ. The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. *J Clin Invest* 1966;45:1608–1614. [PubMed: 5927117]
42. Amanzadeh J, Gitomer W, Zerwekh JE, et al. Effect of high protein diet on stone-forming propensity and bone loss in rats. *Kidney Int* 2003;64:2142–2149. [PubMed: 14633136]
43. Nijenhuis T, Renkema KY, Hoenderop JGJ, et al. Acid-base status determines the renal expression of Ca^{2+} and Mg^{2+} transport proteins. *J Amer Soc Nephrol* 2006;17:617–626. [PubMed: 16421227]
44. Reddy ST, Wang CY, Sakhaee K, et al. Effect of low carbohydrate, high protein diet on acid-base balance, stone-forming propensity and calcium metabolism. *Am J Kid Dis* 2002;40:265–274. [PubMed: 12148098]
45. Zerwekh, JE.; Zou, L.; Pak, CYC., et al. Biochemical and histological assessment of the effects of alkali therapy on bone during high animal protein intake. Presented at the 29th annual meeting of the American Society for Bone and Mineral Research; Honolulu, HI. September 16–16, 2007;
46. Sakhaee K, Maalouf NM, Abrams SA, et al. Effects of potassium alkali and calcium supplementation on bone turnover in postmenopausal women. *J Clin Endocrinol Metab* 2005;90:3528–3533. [PubMed: 15755853]
47. Buck AC, Lote CJ, Sampson WF. The influence of renal prostaglandins on urinary calcium excretion in idiopathic urolithiasis. *J Urol* 1983;129:421–426. [PubMed: 6572732]
48. Raisz, LG.; Martin, TJ. Prostaglandins in bone and mineral metabolism. In: Peck, WA., editor. *Bone and Mineral Research, Annual 2*. Amsterdam: Elsevier Science; 1983. p. 286-310.
49. Fall PM, Breault DT, Raisz LG. Inhibition of collagen synthesis by prostaglandins in the immortalized rat osteoblastic cell line, Pyl1a: structure activity relations and signal transduction mechanisms. *J Bone Min res* 1994;9:1935–1943.
50. Weisinger JR, Alonzo E, Bellorin-Font E, et al. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. *Kidney Int* 1996;49:244–250. [PubMed: 8770975]
51. Ghazali A, Fuentes V, Desaint C, et al. Low bone mineral density and peripheral blood monocytes activation profile in calcium stone formers with idiopathic hypercalciuria. *J Clin Endocrinol Metab* 1997;82:32–38. [PubMed: 8989228]
52. Baggio B, Budakovic A. Fatty acids and idiopathic nephrolithiasis. *Urol Int* 2005;75:97–101. [PubMed: 16123560]
53. Reed BY, Gitomer WL, Heller HJ, et al. Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spinal bone density. *J Clin Endocrinol Metab* 2002;87:1476–1485. [PubMed: 11932268]
54. Raisz LG, Kream BE, Smith MD, et al. Comparison of the effects of vitamin D metabolites on collagen synthesis and resorption of fetal rat bone in organ culture. *Calcif Tissue Int* 1980;32:135–138. [PubMed: 6773630]
55. Broadus AE, Erickson SB, Gertner JM, et al. An experimental human model of 1,25-dihydroxyvitamin D-mediated hypercalciuria. *J Clin Endocrinol Metab* 1984;59:202–206. [PubMed: 6330152]
56. Broadus AE, Insogna KL, Lang R, et al. Evidence for disordered control of 1,25-dihydroxyvitamin D production in absorptive hypercalciuria. *New Eng J Med* 1984;311:73–80. [PubMed: 6330548]
57. Breslau NA, Preminger GM, Adams BV, et al. Use of ketoconazole to probe the pathogenetic importance of 1,25-dihydroxyvitamin D in absorptive hypercalciuria. *J Clin Endocrinol Metab* 1992;75:1446–1452. [PubMed: 1464646]
58. Favus MJ, Karnauskas AJ, Parks JH, et al. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. *J Clin Endocrinol Metab* 2004;89:4937–4943. [PubMed: 15472188]
59. Zerwekh JE, Reed BY, Heller HJ, et al. G.B. Normal vitamin D receptor concentration and responsiveness to 1,25-dihydroxyvitamin D_3 in skin fibroblasts from patients with absorptive hypercalciuria. *Min Elec Metab* 1998;24:307–313.
60. Karnauskas AJ, van Leeuwen JP, van den Bemd GJ, et al. Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. *J Bone Min Res* 2005;20:447–454.
61. Krieger NS, Stathopoulos VM, Bushinsky DA. Increased sensitivity to $1,25(\text{OH})_2\text{D}_3$ in bone from genetic hypercalciuric rats. *Am J Physiol* 1996;271:C130–C135. [PubMed: 8760038]

Figure 1.

The association between customary dietary calcium intake and age-adjusted femoral neck BMD for men with and without a history of kidney stones. Customary dietary calcium intake was determined from self-reported habitual milk consumption. Age-adjusted BMD values are relative to men with no kidney stone history and no habitual milk consumption. Reproduced from *J Bone Min Res* 16:1893–1898, 2001; with permission of the American Society for Bone and Mineral Research.

Figure 2. Microphotographs of cancellous bone from rat femur. (A) Trabecular bone from a rat that had been on a low casein diet for 2 months demonstrating osteoid and osteoblasts (arrow) and normal bone formation. (B) Trabecular bone from a rat that had been on a high casein diet demonstrating a marked increase in the number of active osteoclasts and extent of eroded surface (arrows). Final magnification 160X.